Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib + Daunorubicin + Cytarabine in Newly Diagnosed AML with KIT Overexpression
NCT01806571Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Mar 2015
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nilotinib in acute myeloid leukemia (AML), sponsored by Mayo Clinic. Started Mar 2015; status: completed.
02
Drugs
nilotinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01806571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01806571.